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ventricular mass index (LVMI)). When VEGF was added to the
model, the moderate relationship between serum Ang-1 with
total renal volume and LVMI was lost. Importantly, in our
study there was no association between serum VEGF level and
platelet counts in the autosomal dominant polycystic kidney
disease (ADPKD) study subjects. Moreover, there were no
signiﬁcant differences between levels of serum VEGF measured
in samples collected at baseline and after 18 months in 10
patients ruling out variable ex vivo platelet activation in our
samples. Paired serum and plasma VEGF levels have previously
been shown to correlate in control and colorectal cancer
subjects.3 Both plasma and platelet levels of VEGF and Ang-1
are elevated in hypertensive subjects,4 thus indicating the
apparent utility of measurement of both sera and plasma VEGF.
Although we concur that our results do not permit us to
comment upon the source of angiogenic growth factors, they do
impart new information regarding the relationship of VEGF
with renal and cardiac structure in ADPKD.
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Chronic renal failure induced
by lead
To the Editor: We read with interest the review article
by Evans and Elinder,1 who attempted to challenge the
well-established fact that lead exposure causes chronic renal
failure (CRF). Nevertheless, it seems that the authors missed
some important facts when citing our studies.2–4 In the
paper,1 the authors commented that the studies2–4 were
limited by not measuring glomerular ﬁltration rate (GFR) and
not adjusting for confounding factors (acidosis, inﬂammation,
and hyperparathyroidism). Furthermore, there is limited
knowledge and lack of validation of ethylenediaminetetra-
acetic acid (EDTA) test among CRF patients. These inter-
pretations are not entirely correct.
For example, we have reported3 that GFR improved
signiﬁcantly by the end of the 27th month in patients
receiving EDTA chelation therapy. The mean change in
GFR in the chelation group was 2.1±5.7ml/min, as
compared with 6.0±5.8ml/min in the controls
(Po0.001). The rate of decline in GFR in the chelation
group was also lower than that in the controls during the 24-
month period of repeated chelation therapy or placebo.
Anyway, we reckon that the studies2–4 were not adjusted for
the above-mentioned confounders, but we wonder if the
chronic kidney disease stage 3 of the studied population2–4
could cause any considerable acidosis, inﬂammation, or
hyperparathyroidism. In contrast, advanced-stage chronic
kidney disease or end-stage renal disease5 might be the
exception. Literature data on the validation of the EDTA test
among CRF patients are few, but we have demonstrated6 that
repeated chelation therapy slowed the progression of renal
insufﬁciency in non-diabetic patients with high normal-body
lead burden.
1. Evans M, Elinder C-G. Chronic renal failure from lead: myth or
evidence-based fact? Kidney Int 2011; 79: 272–279.
2. Yu CC, Lin JL, Lin-Tan DT. Environmental exposure to lead and progression
of chronic renal diseases: a four-year prospective longitudinal study.
J Am Soc Nephrol 2004; 15: 1016–1022.
3. Lin JL, Lin-Tan DT, Hsu KH et al. Environmental lead exposure and
progression of chronic renal diseases in patients without diabetes.
N Engl J Med 2003; 348: 277–286.
4. Lin JL, Lin-Tan DT, Li YJ et al. Low-level environmental exposure to lead
and progressive chronic kidney diseases. Am J Med 2006; 119: 707,
e701–709.
5. Lin JL, Lin-Tan DT, Yen TH et al. Blood lead levels, malnutrition,
inflammation, and mortality in patients with diabetes treated by long-term
hemodialysis. Am J Kidney Dis 2008; 51: 107–115.
6. Lin-Tan DT, Lin JL, Yen TH et al. Long-term outcome of repeated lead
chelation therapy in progressive non-diabetic chronic kidney diseases.
Nephrol Dial Transplant 2007; 22: 2924–2931.
Tzung-Hai Yen1,2, Dan-Tzu Lin-Tan1,2 and
Ja-Liang Lin1,2
1Department of Nephrology and Division of Clinical Toxicology, Chang Gung
Memorial Hospital, Taipei, Taiwan and 2School of Medicine, Chang Gung
University, Taoyuan, Taiwan
Correspondence: Ja-Liang Lin, Department of Nephrology and Division of
Clinical Toxicology, Chang Gung Memorial Hospital, 199 Tung Hwa North
Road, Taipei 105, Taiwan. E-mail: jllin99@hotmail.com
Kidney International (2011) 79, 688; doi:10.1038/ki.2010.505
The Authors Reply: We are pleased that Lin et al.1 have
read and commented on our mini review in Kidney
International 2 in which we challenge the often-repeated,
but not very well-founded, view that exposure to lead may
cause chronic renal failure (CRF) in adults. The ﬁnding of Lin
et al. that repeated infusions of ethylenediaminetetraacetic
acid (EDTA) in patients with reduced renal function (serum
creatinine 1.5–3.9mg/dl, estimated glomerular ﬁltration rate
(GFR) 18–56ml/min per 1.73m2) decrease the decline in
estimated renal function compared with controls is remark-
able, to say the least. We argue, however, that the GFR in
these studies was not actually measured, but estimated from
the serum creatinine concentration and creatinine clearance.
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